PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9727420-7 1998 The increases were associated with highly charged molecular forms of decorin and biglycan, indicating modification of the proteins with dermatan sulfate chains of increased sulfation. Dermatan Sulfate 136-152 decorin Homo sapiens 69-76 9727420-9 1998 CONCLUSIONS: The increased dermatan sulfate associated with chronic corneal pathologic conditions results from stromal accumulation of decorin and particularly of biglycan in the affected corneas. Dermatan Sulfate 27-43 decorin Homo sapiens 135-142 8440685-5 1993 Treatment of skin decorin and GAG chains with chondroitinase ABC totally eliminated the ability of these compounds to accelerate thrombin inhibition by heparin cofactor II suggesting that dermatan sulfate was responsible for this action. Dermatan Sulfate 188-204 decorin Homo sapiens 18-25 8440685-1 1993 Two small interstitial dermatan sulfate-containing proteoglycans, biglycan and decorin, are present in extracellular matrices of skin, tendon, ligament, and cartilage. Dermatan Sulfate 23-39 decorin Homo sapiens 79-86 9266027-6 1997 These results suggest that the increased amount of dermatan/chondroitin sulphate in SSc fibroblasts reflects an enhanced expression of decorin core protein. Dermatan Sulfate 51-60 decorin Homo sapiens 135-142 22877511-6 2012 This shows that the decorin protein and the dermatan sulfate chain of decorin have both a structural function and a signaling function. Dermatan Sulfate 44-60 decorin Homo sapiens 70-77 1646824-3 1991 However, heparin and protein-free dermatan sulfate were able to inhibit endocytosis of decorin in a concentration-dependent manner. Dermatan Sulfate 34-50 decorin Homo sapiens 87-94 29111696-0 2017 Sequencing the Dermatan Sulfate Chain of Decorin. Dermatan Sulfate 15-31 decorin Homo sapiens 41-48 29111696-6 2017 By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined. Dermatan Sulfate 228-244 decorin Homo sapiens 220-227 1555588-5 1992 Only a small effect was observed on another dermatan sulphate proteoglycan, PG-S2 (also named decorin). Dermatan Sulfate 44-61 decorin Homo sapiens 76-81 1370306-1 1992 We used a polyclonal antibody and a mixture of three monoclonal antibodies (MAb), all recognizing the protein core of the small dermatan sulfate proteoglycan (DSPG) (known as PG-II or decorin) derived from human skin fibroblasts, to immunolocalize this molecule in the characteristic lesions in Alzheimer"s brain. Dermatan Sulfate 128-144 decorin Homo sapiens 175-180 10536375-7 1999 DCN bearing dermatan-sulfate chains (i.e., skin and cartilage DCN) was about 20-fold more effective in inhibiting cell migration than DCN bearing chondroitin-sulfate chains (i.e., bone DCN). Dermatan Sulfate 12-28 decorin Homo sapiens 0-3 21647927-0 2011 Combining size-exclusion chromatography and fully automated chip-based nanoelectrospray quadrupole time-of-flight tandem mass spectrometry for structural analysis of chondroitin/dermatan sulfate in human decorin. Dermatan Sulfate 178-194 decorin Homo sapiens 204-211 16690200-6 2006 Tumor-associated glycanated decorin was found to contain significant amounts of dermatan sulfate (DS) sequences. Dermatan Sulfate 80-96 decorin Homo sapiens 28-35 16690200-6 2006 Tumor-associated glycanated decorin was found to contain significant amounts of dermatan sulfate (DS) sequences. Dermatan Sulfate 98-100 decorin Homo sapiens 28-35 11855549-1 2002 Decorin, a small proteoglycan containing a dermatan sulfate (DS) chain, is expressed abnormally in human colon cancer stroma. Dermatan Sulfate 43-59 decorin Homo sapiens 0-7 11855549-1 2002 Decorin, a small proteoglycan containing a dermatan sulfate (DS) chain, is expressed abnormally in human colon cancer stroma. Dermatan Sulfate 61-63 decorin Homo sapiens 0-7 10536375-11 1999 Overall, these results show that the inhibitory action of DCN is dependent of substratum binding, is differentially mediated by its glycosaminoglycan side chains (chondroitin-sulfate vs. dermatan-sulfate chains), and is independent of a steric hindrance effect exerted by its glycosaminoglycan side chains. Dermatan Sulfate 187-203 decorin Homo sapiens 58-61 12060613-8 2002 The decorin component of tumor stroma was previously shown to contain high levels of chondroitin sulfate as opposed to dermatan sulfate side chains, and those molecules contained unusually high levels of O- and 6-sulfate linkages. Dermatan Sulfate 119-135 decorin Homo sapiens 4-11 10536375-7 1999 DCN bearing dermatan-sulfate chains (i.e., skin and cartilage DCN) was about 20-fold more effective in inhibiting cell migration than DCN bearing chondroitin-sulfate chains (i.e., bone DCN). Dermatan Sulfate 12-28 decorin Homo sapiens 62-65 10536375-7 1999 DCN bearing dermatan-sulfate chains (i.e., skin and cartilage DCN) was about 20-fold more effective in inhibiting cell migration than DCN bearing chondroitin-sulfate chains (i.e., bone DCN). Dermatan Sulfate 12-28 decorin Homo sapiens 62-65 10536375-9 1999 These data assert that the dermatan-sulfate chains of DCN are responsible for a negative influence on cell migration. Dermatan Sulfate 27-43 decorin Homo sapiens 54-57